Non-Small Cell Lung Cancer Clinical Trial
Official title:
A Phase III, Single-Arm Multicenter Study of Atezolizumab (Anti-PD-L1 Antibody) in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
This is a Phase III, single arm, multicenter study designed to evaluate the efficacy and safety of atezolizumab in high PD-L1 expression, chemotherapy-naïve, without a sensitizing EGFR mutation or ALK translocation patients with stage IV non-squamous or squamous NSCLC.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | August 31, 2027 |
Est. primary completion date | February 28, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - ECOG performance status of 0 or 1. - Histologically or cytologically confirmed, Stage IV non-squamous or squamous NSCLC. - No prior treatment for Stage IV non-squamous or squamous NSCLC. - Patients who have received prior neo-adjuvant, adjuvant chemotherapy, radiotherapy, or chemo-radiotherapy with curative intent for non-metastatic disease must have experienced a treatment free interval of at least 6 months from enrollment since the last chemotherapy, radiotherapy, or chemo-radiotherapy cycle. - Tumor TC3 or IC3, as determined by SP142 performed by a central laboratory on previously obtained archival tumor tissue or tissue obtained from a biopsy at screening. - Measurable disease, as defined by RECIST v1.1. - Adequate hematologic and end-organ function. - Life expectancy =3 months. - For women of childbearing potential: agreement to remain abstinent or use contraception, and agreement to refrain from donating. Exclusion Criteria: - Known sensitizing mutation in the EGFR gene or ALK fusion oncogene. - Symptomatic, untreated, or actively progressing CNS metastases. - Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for =2 weeks prior to enrollment. - Current leptomeningeal disease. - Uncontrolled tumor-related pain. - Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures. - Uncontrolled or symptomatic hypercalcemia. - Malignancies other than NSCLC within 5 years prior to enrollment, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome. - Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within at least 5 months after the last dose of atezolizumab. - History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins. - Known allergy or hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation. - Active or history of autoimmune disease or immune deficiency. - History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. - Positive human immunodeficiency virus (HIV) test result at screening. - Patients with active hepatitis B or active hepatitis C at screening. - Active tuberculosis. - Severe infections within 4 weeks prior to randomization, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia. - Significant cardiovascular disease. |
Country | Name | City | State |
---|---|---|---|
China | Beijing Chest Hospital; Oncology Department | Beijing | |
China | Xuanwu Hospital, Capital Medical University | Beijing City | |
China | The Third Xiangya Hospital Of Central South University | Changsha | |
China | Changzhou First People's Hospital | Changzhou | |
China | Sichuan Cancer Hospital | Chengdu City | |
China | Daping Hospital of Third Military Medical University | Chongqing | |
China | Fujian Cancer Hospital | Fuzhou | |
China | Nanfang Hospital, Southern Medical University | Guangzhou | |
China | The First Affilicated Hospital, Sun Yat-sen University | Guangzhou City | |
China | The Second Affiliated Hospital, Zhejiang University | Hangzhou | |
China | Sir Run Run Shaw Hospital Zhejiang University | Hangzhou City | |
China | Harbin Medical University Cancer Hospital | Harbin | |
China | The First Affiliated Hospital of Anhui Medical University | Hefei | |
China | Anhui Province Cancer Hospital | Hefei City | |
China | Shandong Cancer Hospital | Jinan | |
China | The First Affiliated Hospital Of Jinzhou Medical University | Jinzhou City | |
China | Yunnan Cancer Hospital | Kunming City | |
China | Linyishi Cancer Hospital | Linyi City | |
China | Jiangsu Cancer Hospital | Nanjing City | |
China | Nanjing Chest Hospital | Nanjing City | |
China | Shanghai Chest Hospital | Shanghai | |
China | Cancer Hospital of Shantou University Medical College | Shantou | |
China | Tianjin Cancer Hospital | Tianjin | |
China | Tianjin Medical University General Hospital | Tianjin | |
China | Renmin Hospital of Wuhan University | Wuhan | |
China | Tumor Center,Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan | |
China | The First Affiliated Hospital of Xiamen University | Xiamen | |
China | Xuzhou Central Hospital | Xuzhou |
Lead Sponsor | Collaborator |
---|---|
Hoffmann-La Roche |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall survival (OS) | Overall survival (OS) is defined as the time from atezolizumab initiation to death from any cause. | Atezolizumab initiation to death from any cause (up to approximately 28 months) | |
Secondary | Progression-free survival (PFS) | Progression-free survival (PFS) is defined as the time from atezolizumab initiation to the first occurrence of disease progression or death from any cause (whichever occurs first), as determined by investigators according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1). | Atezolizumab initiation to the first occurrence of disease progression or death from any cause (whichever occurs first), (up to approximately 28 months) | |
Secondary | OS Rate at 1-Year | OS rate at 1-year is defined as the probability of participants who have not experienced death from any cause at 1-year after atezolizumab initiation. | Atezolizumab initiation to 1-year | |
Secondary | OS Rate at 2-Year | OS rate at 2-year is defined as the probability of participants who have not experienced death from any cause at 2-year after atezolizumab initiation. | Atezolizumab initiation to 2-year | |
Secondary | Objective Response Rate (ORR) | Objective response rate (ORR) is defined as the proportion of participants with a complete response (CR) or partial response (PR), as determined by investigators according to RECIST v1.1. | Randomization up to approximately 34 months | |
Secondary | Duration of Response (DOR) | Duration of response (DOR) is defined as the time from the first occurrence of an objective response to disease progression or death from any cause (whichever occurs first), as determined by investigators according to RECIST v1.1. | Randomization up to approximately 34 months | |
Secondary | Percentage of Participants With Adverse Events | Percentage of participants with adverse events. | Randomization up to approximately 34 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |